



(12) Translation of
European patent specification

(11) NO/EP 2906219 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/495 (2006.01)
A61P 17/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.12.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.08.07
(86)	European Application Nr.	13774189.8
(86)	European Filing Date	2013.10.09
(87)	The European Application's Publication Date	2015.08.19
(30)	Priority	2012.10.11, US, 201261712499 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	NeRRe Therapeutics Limited, Stevenage Bioscience Catalyst Office F25 Incubator Building Gunnels Wood Road Stevenage Herts, SG1 2FX, Storbritannia
(72)	Inventor	EMILIANGELO, Ratti, Stevenage Bioscience CatalystOffice F25 Incubator BuildingGunnels Wood Road, StevenageHerts SG1 2FX, Storbritannia MICHAEL, Trower, Stevenage Bioscience CatalystOffice F25 Incubator BuildingGunnels Wood Road, StevenageHerts SG1 2FX, Storbritannia
(74)	Agent or Attorney	Murgitroyd & Company, 165-169 Scotland Street, G58PL GLASGOW, Storbritannia

(54) Title **ORVEPITANT FOR THE TREATMENT OF CHRONIC PRURITUS**

(56) References
Cited: WO-A1-03/066635
ONG: "Investigational and new therapy for atopic dermatitis", IMMUNOLOGY, 2010,
DUFOUR ET AL.: "NUTRITIONAL UP REGULATION...", NUTRITIONAL NEUROSCIENCE,
2010,
WALLENGREN: "TOPICAL APREPITANT...", ARCH. DERMATOL., 2012,
IKOMA: "analysis of mechanism...", J. PHARMAC. SCI., 2009,
DANIELE SANTINI ET AL: "Aprepitant for management of severe pruritus related to biological
cancer treatments: a pilot study", THE LANCET ONCOLOGY, vol. 13, no. 10, 18 September
2012 (2012-09-18), pages 1020-1024, XP055089772, ISSN: 1470-2045, DOI: 10.1016/S1470-
2045(12)70373-X

Misty J Williams-Fritze ET AL: "Maropitant Citrate for Treatment of Ulcerative Dermatitis in Mice with a C57BL/6 Background", , 1 March 2011 (2011-03-01), XP055089823, Retrieved from the Internet: URL:<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061423/pdf/jaalas2011000221.pdf> [retrieved on 2013-11-22]

HONG ET AL: "Management of itch in atopic dermatitis", SEMIN. CUT. ED. SURG., 2011,

ONG: "Emerging drugs for atopic dermatitis", EXPERT OPINIONS ON EM. DRUGS, 2009,

SONJA STÄNDER ET AL: "Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy", PLOS ONE, vol. 5, no. 6, 1 January 2010 (2010-01-01) , pages e10968-e10968, XP055089771, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0010968

SONJA GRUNDMANN ET AL: "Chronic Pruritus: Clinics and Treatment", ANNALS OF DERMATOLOGY, vol. 23, no. 1, 1 January 2011 (2011-01-01), page 1, XP055089640, ISSN: 1013-9087, DOI: 10.5021/ad.2011.23.1.1

"New Animal Drug Application (NADA) of maropitant", NADA 141-263, 2007,

"maropitant EPAR Scientific Discussion WC500061371", L, 2018,

TIAGO TORRES ET AL: "Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 66, no. 1, January 2012 (2012-01), pages e14-e15, XP028342047, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2011.01.016 [retrieved on 2011-01-25]

HAMPTON ET AL.: "Progression of Ulcerative dermatitis...", J. AM. ASS. L.A.SCIENCE, 2012,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. 2-(R)-(4-Fluor-2-metylphenyl)-4-(S)-((8aS)-6-okso-heksahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidin-1-karboksytsyre-[1-(R)-(3,5-bis-trifluormetyl-fenyl)-etyl]-metylamid
 5 (orvepitant) eller et farmasøytisk akseptabelt salt derav for anvendelse i behandlingen av kronisk pruritt som skyldes eller er assosiert med inflammatoriske dermatoser.
2. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 1, hvor inflammatoriske dermatoser velges blant atopisk dermatitt / atopisk eksem, psoriasis,
 10 irritativ dermatitt / kontaktdermatitt, irritativ eksem / kontakteksem, elveblest, tørr hud, uønskede legemiddelreaksjoner, arr, pruritus ani, pruritus scroti, pruritus vulvae og usynlige dermatoser.
3. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 1 eller
 15 2, hvor inflammatorisk dermatose er atopisk dermatitt / atopisk eksem.
4. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 1 eller 2, hvor inflammatorisk dermatose er psoriasis.
- 20 5. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge et hvilket som helst av kravene 1 til 4, hvor det farmasøytisk akseptable salt av forbindelsen er maleat.
6. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge et hvilket
 25 som helst av kravene 1 til 5, hvor forbindelsen er orvepitant-maleat som vannfri krystallform.
7. Farmasøytisk sammensetning for anvendelse i behandlingen av kronisk pruritt som skyldes eller er assosiert med inflammatoriske dermatoser, som omfatter 2-(R)-(4-
 30 Fluoro-2-metylphenyl)-4-(S)-((8aS)-6-okso-heksahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidin-1-karboksytsyre-[1-(R)-(3,5-bis-trifluormetyl-fenyl)-etyl]-metylamid(orvepitant) eller et farmasøytisk akseptabelt salt derav, og én eller flere farmasøytisk akseptable bærere eller eksipienser.